Roche plans to launch Phase 3 studies of its leading obesity candidate this quarter after reporting Tuesday that the drug led to significant weight loss in a mid-stage trial.
The drug, known as CT-388, led to a placebo-adjusted weight loss of 18.3% after 48 weeks in the Phase 2 trial at the highest dose tested of 24 milligrams, the Swiss pharma said.
Roche said that patients were still losing weight at the end of the study period. Just under 6% of patients on the treatment dropped out of the trial due to side effects, which Roche said were largely the gastrointestinal symptoms seen broadly with new weight loss treatments, versus 1.3% of those in the placebo group.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
Individual plans
Group plans
To read the rest of this story subscribe to STAT+.